secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2026-05-19T12:38:18+00:00
Accession:  0001493152-26-024363
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device
--------------------------------------------------------------------------------

- Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
- Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
- Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).
- Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/0001493152-26-024363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer